A case control study of role of lipid profile in polycystic ovarian syndrome: is there any role in non-obese polycystic ovary syndrome?


  • Soumya Ranjan Panda Department of Obstetrics and Gynecology, AIIMS, Jodhpur, Rajasthan, India
  • Prashant Kumar Rout Department of Obstetrics and Gynecology, Veer Surendra Sai Institute of Medical Sciences and Research, Burla, Odisha, India
  • Charu Chandra Department of Obstetrics and Gynecology, AIIMS, Jodhpur, Rajasthan, India




PCOS, Lipid profile, triglyceride, cholesterol, HDL, LDL, VLDL


Background: Polycystic ovary syndrome (PCOS) is characterized by hyperinsulinemia, impaired glucose tolerance, obesity, hyperandrogenism and abnormal lipid profile. Most of the studies involving lipid profile in PCOS are confounded by the factor of obesity. Here in our study we have tried to compare lipid profile in PCOS cases and healthy controls excluding obesity as a confounding factor.

Methods: This is a case control study done between January 2013 to january2014 in VSS MCH, Burla, Odisha, India. The cases(n=50) diagnosed as PCOS based on Rotterdam's criteria and 50 controls of equivalent age group and body mass index without any endocrinopathy and not on hormonal therapy were selected. Lipid profile was compared for both the groups.

Results: The Mean level of total cholesterol in the study and control group is 202.12±40.18 mg/dl and 171.48±17.74 mg/dl respectively and this is statistically highly significant (p value < 0.0001). Similarly the mean of triglyceride level in cases and controls is 162.38 ± 70.40 mg/dl and 131.46 ± 27.16 mg/dl respectively which is also statistically significant (p- value = 0.0046). In contrast to the above finding the change in mean level of HDL, LDL and VLDL is statistically not significant. So it’s found that the atherogenic lipid profile found in PCOS patients is independent of their age and body mass index.

Conclusions: So we recommend that both lean as well as obese PCOS patients should be screened for lipid profile to prevent cardiac complications.


Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Consensus on women's health aspects of polycystic ovary syndrome (PCOS) Hum Reprod. 2012;27:14-24.

Adams J, Franks S, Polson DW, Mason HD, Abdulwahid N, Tucker M, et al. Multi follicular ovaries: clinical and endocrinefeatures and response to pulsatile gonadotropin releasing hormone. Lancet. 1985;2:1375-9.

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Exess Society guideline. J Clin Endocrinol Metab. 2006;91:4237-45.

Dunaif A, Segal K, Futterweit W, Dobrjanky A. Profound peripheral resistance independent of obesity in polycystic ovary syndrome. Diabetes. 1989;38:1165-74.

Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocr. 2006;30:13-7.

Chang RJ. A practical approach to the diagnosis of polycysticovary syndrome. Am J Obstet Gynecol. 2004;191:713-7.

Richardson MR. Current perspectives in polycystic ovary syndrome. Am Fam Physician. 2003;68:697-704.

Lambrinoudak I, Christodoulakas G, Rizos D, Eunomou E, Afgeitis J, Vlachou S. Endogenous sex hormones and risk factors for atherosclerosis in health Greek post-menopausal women. Eur J. Endocrinol. 2006:154(6);907-16.

Xiang SK, Hua F, Tang Y, Jiang XH, Zhuang Q, Qjan FJ. Relationship between serum lipoprotein ratios and insulin resistance in polycystic ovary syndrome. Int J Endocrinol 2012;2012:173281.

Gateva A, Kamenov Z. Cardiovascular Risk Factors in Bulgarian Patients with Polycystic Ovary Syndrome and/or Obesity. Obstet Gynecol Int 2012;ArticleID:306347.

Cristian-Ioan I, Nicolae C, Dan M. Lipid Parameters in Patients with Polycystic Ovary Syndrome, Applied Medical Informatics. 2012;31(4):27-32.

Leila A, Mohammad RS, Fatemeh O, Koorosh K, Haleh M. Lipid Profile in Women with Polycystic Ovary Syndrome; Crescent Journal of Medical and Biological Sciences. 2014:1(4):147-50.

Taponen S, Martikainen H, Jarvelin MR, Sovio U, Laitinen,A, Pouta A, et al . Metabolic cardiovascular disease risk factors in women with self reported symptoms of Oligomenorrhea and Hirsuitism. J. Clin. Endocrinol. Metab. 2004;89(5):2114-8.

Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab. 2007;93:470-6.






Original Research Articles